← Back to Search

Procedure

ECMO for ARDS (ULTIMATE Trial)

N/A
Waitlist Available
Led By Niall Ferguson, MD, MSc
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights

ULTIMATE Trial Summary

This trial is testing whether using a specific type of ventilation (ultra-protective ventilation) with ECMO support can help improve outcomes for people with early moderate-severe ARDS, compared to using the best current conventional ventilation.

ULTIMATE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients recruited for the study
Proportion of patients adhering to the study protocol
Proportion of patients crossing over to VV ECMO
Secondary outcome measures
Health-related quality of life
Length of stay
Mortality
+3 more

ULTIMATE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ultra-protective ventilation with ECMOExperimental Treatment1 Intervention
Group II: Best conventional ventilationActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venovenous ECMO
2023
N/A
~5060

Find a Location

Who is running the clinical trial?

University of TorontoLead Sponsor
689 Previous Clinical Trials
1,018,571 Total Patients Enrolled
University Health Network, TorontoOTHER
1,468 Previous Clinical Trials
484,418 Total Patients Enrolled
Niall Ferguson, MD, MScPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
6,584 Total Patients Enrolled

Media Library

Ultra-Low Tidal Volume Mechanical Ventilation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04832789 — N/A
Acute Respiratory Distress Syndrome Research Study Groups: Ultra-protective ventilation with ECMO, Best conventional ventilation
Acute Respiratory Distress Syndrome Clinical Trial 2023: Ultra-Low Tidal Volume Mechanical Ventilation Highlights & Side Effects. Trial Name: NCT04832789 — N/A
Ultra-Low Tidal Volume Mechanical Ventilation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04832789 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrollments for this clinical trial currently being accepted?

"Per the clinicaltrials.gov platform, this investigation is not currently enrolling volunteers. The trial was inaugurated on June 1st 2021 and concluded its recruitment phase in April of that year. Despite no longer accepting participants for the current study, there are still 90 active trials recruiting patients at present."

Answered by AI

What is the aim of this research endeavor?

"The primary assesment of this two year trial is the adherence to its protocol. Secondary measures include occurrences of non-pulmonary organ dysfunction, barotrauma incidents, and changes in quality of life as quantified by EQ-5D telephone interviews."

Answered by AI

How many health care facilities are conducting this research endeavor?

"This medical trial is running at 15 sites, with New york Presbyterian Hospital in the Big Apple, University of Alberta Hospital in Edmonton and OHSU hospital in Portland being amongst them."

Answered by AI
~19 spots leftby Apr 2025